INBRAIN Neuroelectronics careers

WHY NOW? WHAT IS THE CHALLENGE?


With more than 35% of the population afflicted, the cost of brain disorders is about 800 billion euros/year in each of Europe and the USA. The cost of drugs is about 20% of this financial burden, with some of their side effects delivering additional cost*.


Bioelectrical implants could be the faster, safer and side-effect free alternative to conventional medicines. The existing brain interfaces are all metal-based, with considerable restrictions for miniaturization and signal resolution, therefore limiting their therapeutic effect.

We are developing the next generation of neuroelectronic therapies powered by machine learning. Our graphene-brain interfaces have the capability of reading at a resolution never seen before, as well as detecting therapy-specific biomarkers and triggering highly focal adaptive neuromodula-
tion for increased outcomes in personalised neurological therapies.